Eton Pharmaceuticals (ETON) vs Phibro Animal Health (PAHC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Eton Pharmaceuticals (ETON) has outperformed Phibro Animal Health (PAHC) over the past year, gaining 161.6% versus a gain of 0.8%. Over five years, ETON leads with a +950.9% price change compared with +71.6% for PAHC. Eton Pharmaceuticals is the larger company by market cap ($1.56 billion vs $1.52 billion), about 1.0 times the size.
On valuation, Phibro Animal Health trades at a lower forward P/E (9.7x vs 21.2x for Eton Pharmaceuticals). Phibro Animal Health pays a dividend yielding 1.28%, while Eton Pharmaceuticals does not currently pay one. Phibro Animal Health converts more of its revenue into profit, with a net margin of 6.6% versus -5.8%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ETON | PAHC |
|---|---|---|
| Share price | $54.75 | $37.40 |
| Market cap | $1.56B | $1.52B |
| 1-day change | -0.24% | -0.85% |
| YTD return | +223.77% | +0.11% |
| 1-year return | +161.59% | +0.78% |
| 5-year return | +950.86% | +71.56% |
| P/E ratio (TTM) | 136.88 | 15.39 |
| Forward P/E | 21.22 | 9.73 |
| EPS (TTM) | $0.40 | $2.43 |
| Dividend yield | 0.00% | 1.28% |
| Annual dividend | $0.00 | $0.48 |
| Revenue (latest FY) | $79.95M | $1.52B |
| Revenue growth (YoY) | +104.94% | +17.12% |
| Net income (latest FY) | $-4.60M | $99.72M |
| Gross margin | 53.46% | 33.76% |
| Operating margin | -1.06% | 12.81% |
| Net margin | -5.75% | 6.57% |
| 52-week high | $66.37 | $60.08 |
| 52-week low | $14.27 | $28.25 |
| Distance from 52-week high | -17.51% | -37.75% |
| Analyst consensus | strong_buy | hold |
| Avg. price target upside | +29.68% | +17.65% |
| Average volume | 609.36K | 236.19K |
| Shares outstanding | 28.58M | 21.11M |
| Employees | 44 | 2,605 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ETON has outperformed PAHC by 160.8 percentage points over the past year.
- Eton Pharmaceuticals trades at a higher earnings multiple (136.9x vs 15.4x trailing P/E).
- Phibro Animal Health offers a meaningfully higher dividend yield (1.28% vs 0.00%).
- Phibro Animal Health is more profitable, keeping 6.6 cents of every revenue dollar as net income versus -5.8 cents for Eton Pharmaceuticals.
- Eton Pharmaceuticals grew revenue faster in its latest fiscal year (+104.94% vs +17.12%).
About Eton Pharmaceuticals
ETON stock →Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1.
Health Care · Biotechnology: Pharmaceutical Preparations · 44 employees
About Phibro Animal Health
PAHC stock →Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Latin America and Canada, Europe, the Middle East, Africa, and the Asia Pacific. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Health Care · Biotechnology: Pharmaceutical Preparations · 2,605 employees
ETON vs PAHC FAQ
Which is bigger, Eton Pharmaceuticals or Phibro Animal Health?
Eton Pharmaceuticals (ETON) is larger, with a market capitalization of $1.56B compared with $1.52B for Phibro Animal Health (PAHC).
Which stock has performed better over the past year, ETON or PAHC?
ETON returned +161.59% over the past 12 months, compared with +0.78% for PAHC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ETON or PAHC?
PAHC has the lower trailing P/E at 15.4, versus 136.9 for ETON. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Which pays a higher dividend, Eton Pharmaceuticals or Phibro Animal Health?
Phibro Animal Health pays a dividend yielding 1.28%, while Eton Pharmaceuticals does not currently pay a regular dividend.
Are Eton Pharmaceuticals and Phibro Animal Health in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.